摘要
对于充血性心力衰竭(CHF),尽管药物治疗取得了一些进展,但对纽约心脏病学会分级为心功能Ⅲ或Ⅳ级的患者预后仍差,5年存活率低,活动耐量受限。近年来,心脏再同步化治疗(CRT)已被多个临床实验证明是药物治疗效果差伴严重室间传导阻滞的CHF患者一种有效的治疗方法,虽然面临一些问题,仍然为心力衰竭治疗开辟了新的途径。现就CRT在CHF中的应用现状及存在的争议予以综述。
Despite advances in pharmacological management of chronic congestive heart failure （CHF） ,the patients with New York Heart Association （NYHA） Ⅲ or Ⅳ have bad prognosis,whose survival rate for 5 years is low and their exercise capacity is restricted. In recent years, cardiac resynchronization therapy （CRT） have been proved to be an effective treatment for CHF patients who dont respond well to medical treatment and have ventricular dyssynchrony in many large-scale clinical trials. Though CRT faces some problems,it remains to be a new approach to CHF therapy. This review discussed the current application of CRT in ＇CHF and some disputes in this respects.
出处
《医学综述》
2008年第12期1837-1839,共3页
Medical Recapitulate
关键词
心脏再同步化治疗
心力衰竭
QRS间期
植入型心律转复除颤器
Cardiac resynchronization therapy
Congestive heart failure
QRS duration
Implantable cardioverter defibrillator
